Pandemic Hits: Evaluation of an Antimicrobial Stewardship Program Website for Hospital Communication During the COVID-19 Pandemic Phone: (919) 681-3357



Duke Antimicrobial Stewardship and Evaluation Team

Abstract

Background:

Antibiotic Stewardship Programs (ASPs) assist front-line clinicians in synthesizing emerging data and establishing best practices. Our ASP team directly maintained and edited an internal web application, Duke CustomID[®], to disseminate updated guideline, policy, and drug information during COVID-19. We aimed to describe website engagement and maintenance during the dynamic pandemic period.

Methods

We performed a descriptive, time-series analysis using Google Analytics software to measure engagement with Duke CustomID[®] during a 1-year pre-pandemic period through the Omicron surge: January 2019 to March 2022. We measured total page views (or "hits"), COVID-specific page hits, and days requiring COVID-specific page edits by week. Given fluctuations in hospitalization rates, we defined the primary outcome as the rate of hits divided by total hospitalizations. Weekly data were assessed graphically with positive COVID tests and COVID hospitalizations. We used negative binomial regression to quantify the association between COVID hospitalizations and hit rates and to trend engagement over time, adjusted for seasonality. We stratified data by COVID page and calculated a hit/edit ratio.

Results:

Engagement with CustomID[®] increased during the pandemic period, especially during surges (Figure). Hits in the pre-pandemic period were median 1707 (range 1165-2354) per week, and hit rates median 1.95 per hospitalization (range 1.40-2.86). Peaks were observed in March 2020 (hit rate 4.59) and January 2022 (hit rate 3.87). On average, for every 100 COVID hospitalizations, the hit rate increased by 0.08 (0.004-0.16, p=0.04). Engagement slowly increased over the study period (relative rate week 1 versus 170: 1.15, 95% confidence interval 1.02-1.28, p=0.02). COVID page edits per week had a median of 2 (range 0-12). Adult Inpatient Guidelines and COVID Monoclonal Antibody pages had highest use (Table).

Conclusions:

Our ASP's website was a highly utilized, practical tool for disseminating practice-changing information during the pandemic. Use increased over time and especially during surges. An electronic reference customized for local practice and rapidly updated by ASPs offers critical support for front-line clinicians.

Background

- Duke CustomID® is an internal web application designed to disseminate institution-specific clinical guidance for antimicrobials (e.g. local guidelines, antibiograms, dosing, and hospital policy).
- Clinical management of COVID-19 required frequent changes in practice recommendations including new therapeutics.
- MAIN AIM: To quantify user engagement and effort required to maintain CustomID preceding and during the COVID-19 pandemic.

Results

Perez R¹, Yarrington M¹, Adams M¹, Davis A¹, Deri C¹, Drew RH¹, Smith M², Spivey J¹, Wrenn R¹, Moehring RW¹

1- Division Of Infectious Diseases, Duke University Medical Center, Durham, NC, USA; 2- Division Of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC, USA; 3- Campbell University College of Pharmacy and Health Sciences Buies Creek, NC, USA

- Median CustomID[®] hits in the pre-pandemic period were 1707 per week (range 1165-2354), and median hit rates were 1.95 per hospitalization (range 1.40-2.86)
- During COVID-19, peak hit rates occurred in March 2020 (4.59) and January 2022 (3.87) (**Figure**).
- Hit rates increased by 0.08 (0.004-0.16, p=0.04) for every 100 COVID hospitalizations.
- Engagement slowly increased over the study period: relative hit rate week 1 versus 170: 1.15 (95% confidence interval 1.02-1.28, p=0.02)
- Site maintenance required a median of 2 COVID page edits per week (Figure, Table):
- Guideline pages were efficient in hits/edit ratio due to high engagement.
- Monoclonal antibody page required many edits but also had high engagement.
- COVID Research Protocol list required many edits but had limited engagement.

Table. COVID-19-specific pages on Duke CustomID with total hits, edits, and ratio

Page Name	Date of Initial Posting	Total Hits	Total Edits	Hits/Edits Ratio
All Guideline Pages (N=7)		8311	195	42
Adult Hospitalized COVID Guideline	3/20/2020	4120	29	142
Ambulatory COVID Guideline	12/29/2021	1152	11	104
COVID Research Protocols	3/23/2020	1282	133	9
Pediatric COVID Guideline	3/24/2020	502	13	38
COVID Prophylaxis Guideline	3/20/2020	330	4	82
COVID Antimicrobial Guideline	3/20/2020	254	3	84
Asymptomatic COVID Guideline	1/17/2022	106	1	106
All Drug Pages (N=8)		8247	134	61
COVID Monoclonal Antibodies	11/10/2020	2659	50	68
Remdesivir	5/12/2020	2216	23	96
COVID Vaccines	12/12/2020	1478	32	46
Baricitinib	11/20/2020	1021	7	145
Tocilizumab	7/1/2021	297	8	37
Paxlovid	12/22/2021	272	5	54
Molnupiravir	12/27/2021	179	4	44
Convalescent Plasma	8/31/2020	125	5	25

MBA is founder and CEO of Custom Clinical Decision Support Inc,; RHD American College of Clinical Pharmacists (Publication royalties), Takeda (Advisor/Consultant), UpToDate (publication royalties); RWM UpToDate, inc. (Author Royalties), MJS Merck Pharmaceuticals Grant/Research Support, Pfizer pharmaceuticals Grant/Research Support





Reinaldo.Perez@duke.edu **DUMC Box 103259 Room 170 Hanes House** Durham, NC 27710

DukeHealth